Cargando…

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder

INTRODUCTION: The efficacy and of current antidepressants is insufficient. Esketamine, a new antidepressant administered by nasal route, is available since 2019 in the management of resistant characterized depressive episodes. OBJECTIVES: To evaluate the response profile of patients to Esketamine in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faisant, S., Crublet, P., Bellay, R., Langrée, B., Marie, N., Rojo-Bouton, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567366/ http://dx.doi.org/10.1192/j.eurpsy.2022.1417

Ejemplares similares

Difficulties in maintaining electroconvulsive treatment (ECT) in a psychiatric hospital during covid19 pandemic
por: Rojo, M., et al.
Publicado: (2021)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
por: Wattinne, E. Gaudre, et al.
Publicado: (2021)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

Clinical efficacy and tolerability of Esketamine: a case series
por: Passani, C., et al.
Publicado: (2022)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
por: Basto, M. D. R. D. R. F. D. A., et al.
Publicado: (2023)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
por: Martiadis, V., et al.
Publicado: (2022)

Adjunctive short- and long-term combination treatment of esketamine and VNS in difficult to treat depression (DTD)
por: Kavakbasi, E., et al.
Publicado: (2023)

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021)

Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
por: Liu, Peng, et al.
Publicado: (2022)

Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
por: Daly, Ella J., et al.
Publicado: (2021)

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
por: Veraart, J.K.E., et al.
Publicado: (2023)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
por: Gastaldon, C., et al.
Publicado: (2019)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
por: Martiadis, V., et al.
Publicado: (2023)

Intranasal Esketamine administration in catatonia: a case report.
por: Romay, J., et al.
Publicado: (2023)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
por: Capuzzi, Enrico, et al.
Publicado: (2021)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis
por: Samalin, L., et al.
Publicado: (2023)

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
por: Young, Allan H, et al.
Publicado: (2023)

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
por: Borentain, Stephane, et al.
Publicado: (2021)

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
por: Rognoni, Carla, et al.
Publicado: (2023)

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
por: Vasiliu, Octavian
Publicado: (2023)

The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
por: Dijkstra, Francis M, et al.
Publicado: (2022)

Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression
por: Lan, Xiaofeng, et al.
Publicado: (2023)

The cognitive effects of esketamine: what do we know so far?
por: Barbosa, M., et al.
Publicado: (2022)

Gender differences in response and remission rates among patients receiving esketamine
por: Guterman, A. T., et al.
Publicado: (2023)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
por: Fu, Dong-Jing, et al.
Publicado: (2023)

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
por: Salahudeen, Mohammed S, et al.
Publicado: (2020)

Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
por: Degerlund Maldi, Kinza, et al.
Publicado: (2021)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
por: Olivola, Miriam, et al.
Publicado: (2022)

A 28-Day, Randomized, Controlled, Single-Blind, Phase 2 Study in Treatment-Resistant Major Depressive Disorder (TRD) Patients Receiving Intranasal Esketamine Comparing Addition of Almond Therapy TM with Treatment-as-Usual (TAU)
por: Chue, P., et al.
Publicado: (2023)

The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
por: Liu, Haiyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_24scun6tdnmpkdsjuqdmiveqon